Literature DB >> 16928150

Pharmacokinetic and pharmacodynamic characteristics of medications used for moderate sedation.

Tong J Gan1.   

Abstract

The ability to deliver safe and effective moderate sedation is crucial to the ability to perform invasive procedures. Sedative drugs should have a quick onset of action, provide rapid and clear-headed recovery, and be easy to administer and monitor. A number of drugs have been demonstrated to provide effective sedation for outpatient procedures but since each agent has its own limitations, a thorough knowledge of the available drugs is required to choose the appropriate drug, dose and/or combination regimen for individual patients. Midazolam, propofol, ketamine and sevoflurane are the most frequently used agents, and all have a quick onset of action and rapid recovery. The primary drawback of midazolam is the potential for accumulation of the drug, which can result in prolonged sedation and a hangover effect. The anaesthetics propofol and sevoflurane have recently been used for sedation in procedures of short duration. Although effective, these agents require monitored anaesthesia care. Ketamine is an effective agent, particularly in children, but there is concern regarding emergence reactions. AQUAVAN injection (fospropofol disodium), a phosphorylated prodrug of propofol, is an investigational agent possessing a unique and distinct pharmacokinetic and pharmacodynamic profile. Compared with propofol emulsion, AQUAVAN is associated with a slightly longer time to peak effect and a more prolonged pharmacodynamic effect. Advances in the delivery of sedation, including the development of new sedative agents, have the potential to further improve the provision of moderate sedation for a variety of invasive procedures.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16928150     DOI: 10.2165/00003088-200645090-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  100 in total

1.  Practice guidelines for sedation and analgesia by non-anesthesiologists.

Authors: 
Journal:  Anesthesiology       Date:  2002-04       Impact factor: 7.892

2.  A potential mechanism of propofol-induced pain on injection based on studies using nafamostat mesilate.

Authors:  M Nakane; H Iwama
Journal:  Br J Anaesth       Date:  1999-09       Impact factor: 9.166

3.  Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%.

Authors:  Catherijne A J Knibbe; Klaas P Zuideveld; Joost DeJongh; Paul F M Kuks; Leon P H J Aarts; Meindert Danhof
Journal:  Clin Pharmacol Ther       Date:  2002-12       Impact factor: 6.875

Review 4.  Update and review of moderate and deep sedation.

Authors:  Suzanne B Karan; Peter L Bailey
Journal:  Gastrointest Endosc Clin N Am       Date:  2004-04

Review 5.  Sevoflurane. A review of its pharmacodynamic and pharmacokinetic properties and its clinical use in general anaesthesia.

Authors:  S S Patel; K L Goa
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

6.  Changing patterns of sedation and monitoring practice during endoscopy: results of a nationwide survey in Switzerland.

Authors:  L T Heuss; F Froehlich; C Beglinger
Journal:  Endoscopy       Date:  2005-02       Impact factor: 10.093

7.  Propofol: clinical strategies for preventing the pain of injection.

Authors:  R P Scott; D A Saunders; J Norman
Journal:  Anaesthesia       Date:  1988-06       Impact factor: 6.955

Review 8.  Analgesia and sedation in critically ill patients.

Authors:  Bernhard Walder; Martin R Tramèr
Journal:  Swiss Med Wkly       Date:  2004-06-12       Impact factor: 2.193

9.  Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects.

Authors:  P J Pentikäinen; L Välisalmi; J J Himberg; C Crevoisier
Journal:  J Clin Pharmacol       Date:  1989-03       Impact factor: 3.126

10.  Intravenous midazolam for upper gastrointestinal endoscopy: a study of 800 consecutive cases relating dose to age and sex of patient.

Authors:  G D Bell; G P Spickett; P A Reeve; A Morden; R F Logan
Journal:  Br J Clin Pharmacol       Date:  1987-02       Impact factor: 4.335

View more
  24 in total

Review 1.  Dexmedetomidine: a review of its use for sedation in mechanically ventilated patients in an intensive care setting and for procedural sedation.

Authors:  Sheridan M Hoy; Gillian M Keating
Journal:  Drugs       Date:  2011-07-30       Impact factor: 9.546

2.  Breakdown in cortical effective connectivity during midazolam-induced loss of consciousness.

Authors:  Fabio Ferrarelli; Marcello Massimini; Simone Sarasso; Adenauer Casali; Brady A Riedner; Giuditta Angelini; Giulio Tononi; Robert A Pearce
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-25       Impact factor: 11.205

3.  [Drugs for intravenous induction of anesthesia: ketamine, midazolam and synopsis of current hypnotics].

Authors:  E Halbeck; C Dumps; D Bolkenius
Journal:  Anaesthesist       Date:  2018-08       Impact factor: 1.041

4.  Fospropofol disodium (lusedra) injection for anesthesia-care sedation: a clinical review.

Authors:  Ramy Boules; Andrew Szkiladz; Anna Nogid
Journal:  P T       Date:  2012-07

5.  Dexmedetomidine: a guide to its use for sedation in the US.

Authors:  Gillian M Keating; Sheridan M Hoy; Katherine A Lyseng-Williamson
Journal:  Clin Drug Investig       Date:  2012-08-01       Impact factor: 2.859

6.  Safety of midazolam for sedation of HIV-positive patients undergoing colonoscopy.

Authors:  E S Backman; V A Triant; J M Ehrenfeld; Z Lu; P Arpino; E Losina; R T Gandhi
Journal:  HIV Med       Date:  2013-01-18       Impact factor: 3.180

7.  Predictors of hemodynamic compromise with propofol during defibrillator implantation: a single center experience.

Authors:  Khyati Pandya; Mehul B Patel; Jaya Natla; Abhijeet Dhoble; Terry Habetler; Jeffrey Holliday; Renee Janes; Sujeeth R Punnam; Joseph C Gardiner; Ranjan K Thakur
Journal:  J Interv Card Electrophysiol       Date:  2009-03-05       Impact factor: 1.900

8.  Perspectives on the role of fospropofol in the monitored anesthesia care setting.

Authors:  Joseph V Pergolizzi; Tong J Gan; Stanford Plavin; Sumedha Labhsetwar; Robert Taylor
Journal:  Anesthesiol Res Pract       Date:  2011-04-14

9.  Fospropofol: clinical pharmacology.

Authors:  Girish M Bengalorkar; K Bhuvana; N Sarala; Tn Kumar
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2011-01

10.  Clinical and critical care concerns in severely ill obese patient.

Authors:  Sukhminder Jit Singh Bajwa; Vishal Sehgal; Sukhwinder Kaur Bajwa
Journal:  Indian J Endocrinol Metab       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.